Adult Dosing
Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
- Apply a thin layer to the affected skin qd-bid
- Max: 50 g/wk for 2 consecutive wks
- Not to be used with occlusive dressings
Pediatric Dosing
- Safety and effectiveness in pediatric patients <12 years of age have not been established
Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
- Children >12yrs: Apply a thin layer to the affected skin qd-bid
- Max: 50 g/wk for 2 consecutive wks
- Not to be used with occlusive dressings
[Outline]
See Supplemental Patient Information
- Systemic absorption of topical halobetasol may produce hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria. It may result in glucocorticosteroid insufficiency after withdrawal of treatment
- Topical application of halobetasol to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression using urinary free-cortisol tests, A.M. plasma cortisol, and ACTH stimulation. If HPA axis suppression is noted, withdraw and substitute with a lower potency drug
- Treatment beyond 2 wks is not recommended due to potential of the drug for HPA axis suppression and only small areas should be treated at one time. Consider reassessment of the diagnosis if no improvement is seen within 2 weeks of therapy
- Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios
- Appropriate anti-fungal or anti-bacterial agent should be used to treat concomitant skin infections. If no favorable response occurs, discontinue halobetasol until the infection has been adequately controlled
- Discontinue therapy if irritation develops and institute appropriate treatment
Supplemental Patient Information
- Advise patients not to bandage, cover, or wrap the treated skin unless directed by the physician
- Advise patients to promptly inform their physicians for any signs of local adverse reactions
- Instruct patients to avoid using on the face, groin, or in the axillae
Pregnancy Category:C
Breastfeeding: Safety unknown. Short-term application of topical corticosteroids is not expected to pose a risk to the breastfed infant by passage into breastmilk. However, caution is advised if the application is to the mother's nipple or areola because the breastfed infant may have significant absorption. Topical corticosteroid should be wiped off thoroughly prior to nursing if applied to the breast or nipple area. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 07 January 2011). Manufacturer advises caution while administering to nursing women.
Pricing data from www.DrugStore.com in U.S.A.
- Ultravate 0.05 % OINT [Tube] (RANBAXY LABORATORIES)
50 % = $169.99
150 % = $449.97 - Halobetasol Propionate 0.05 % OINT [Tube] (PERRIGO PHARMACEUTICALS)
15 % = $26.99
45 % = $59.97 - Ultravate 0.05 % CREA [Tube] (RANBAXY LABORATORIES)
50 % = $156.79
150 % = $447.97 - Ultravate 0.05 % CREA [Tube] (RANBAXY LABORATORIES)
15 % = $59.99
45 % = $169.98 - Ultravate 0.05 % OINT [Tube] (RANBAXY LABORATORIES)
15 % = $68.32
45 % = $188.15
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
